Matches 401 - 450 out of 569 < 1 2 3 4 5 6 7 8 9 10 11 12 >
Match Document Document Title
5272070 Method for the preparation of cell lines producing Man.sub.3 GlcN.sub.ac 2 asparagine-linked gylcans and cell lines produced thereby  
Disclosed is the preparation of eukaryotic cells which are capable of producing smaller and less heterogenic N-linked glycans, particularly glycans having the structure Man 3 GlcNAc 2 . In...
5270040 Vectors and compounds for expression of human protein C  
The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that...
5270198 DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells  
A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glycosylation sites in regions that are not glycosylated in the native molecule....
5266474 Balanced inducible transcription system  
A balanced constitutive inducible transcriptional control system is provided to facilitate the expression of polypeptides incompatible with recombinant host cells. Use of this system has, for the...
5260059 Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor  
5258298 Deletion and glycosylation mutant of human tissue plasminogen activator  
Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one...
5258180 Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment  
A tissue plasminogen activator (t-PA) variant is prepared that has an amino acid deletion at positions 466 to 470 of the corresponding wild-type t-PA. This alteration renders the variant fibrin...
5246850 DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells  
Biologically active tissue plasminogen activator (t-PA) variants with decreased clearance as compared to wild-type t-PA are prepared, including variants that have one or more amino acid alterations...
5244800 Crystals of human complement factor D that are triclinic  
Crystals of human complement factor D that are triclinic are disclosed. They are made by a method of crystallization known as the "hanging drop" technique. The technique uses 1.0-1400 mM NaCl and...
5244676 Modified tissue plasminogen activator with modified glycosylation site  
A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a fibronectin finger-like domain F, a growth factor domain GF, a sequence of two K2 kringle regions and a...
5244806 DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells  
The invention discloses modified forms of the enzyme tissue plasminogen activator (t-PA) in which recombinant DNA techniques are utilized to modify the structure of the t-PA cDNA to express a...
5242819 DNA molecules encoding hybrid proteins of tissue plasminogen activator and urokinase  
Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA...
5238833 Molecular cloning and expression in industrial Bacillus species  
Novel methods and novel industrial unicellular microorganism strains, particularly industrial Bacillus strains, are provided for enhanced production of endogenous and exogenous polypeptides....
5234686 Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment  
A purified fibrinolytically active degraded species of tissue-type plasminogen activator comprising a fibrinolytically intact B chain of native t-PA linked to kringle 2 as the only functionally and...
5232847 Human tissue plasminogen activator analogue having substitutions at amino acid positions 66, 67 and 68  
Tissue plasminogen activator (t-PA) analogues have at least one substitution in the growth factor (GF) domain that at least partially reduces hepatic receptor binding without substantially...
5227297 Affinity purification ligands  
A tripeptide ligand of the formula -X-Y-Argininal is used to purify plasminogen activators.
5223256 Thrombolytically active non-glycosylated protein  
A new thrombolytically active protein is not glycosylated and consists of the following amino acid sequence: ##STR1## or said amino acid sequence with an additional N-terminal methionine. DNA...
5223422 t-PA mutant GK1L  
The invention concerns a recombinant DNA which codes for a protein with the domains G, K1 and L of t-PA in which the sequences coding for the domains K2 and F of the wild-type t-PA gene or the...
5221622 170kD membrane-bound protease useful in diagnosis of malignant cellular transformation  
A novel 170 kD membrane protease is isolated from malignant human melanoma cell line LOX and RPMI7951. The protease is useful in a method of diagnosing cellular transformation.
5219569 Protease resistant urokinase  
Novel single-chain protease resistant urokinase derivatives are provided. In particular, derivatives are provided wherein the Lys 135 Lys 136 and Arg 156 to Lys 158 sites are rendered less...
5217891 DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides  
DNA constructs that are useful for providing secretory expression of heterologous polypeptides in yeast comprising a DNA sequence that includes a Kluyveromyces α-factor leader sequence linked to...
5215908 Process for recovery and purification of chymosin  
This invention provides a method of recovering and purifying chymosin from fermentation used for microbial production of chymosin. The fermentation mixture is filtered to provide a filtrate...
5210037 Method to enhance TPA production  
A medium supplement which promotes the secretion of tPA from cells producing this protein natively or by virtue of recombinant transformation without the concomitant addition of contaminating...
5204256 Process for the purification of plasminogen activator inhibitor 2 (PAI-2)  
A process for the purification of plasminogen activator inhibitor 2 (PAI-2) including the steps of preincubating a PAI-2-containing solution with a compound which cleaves disulfide linkages, mixing...
5204255 Hybrid tissue plasminogen activator/urokinase polypeptides  
A hybrid plasminogen activator-like polypeptide comprising a polypeptide region responsible for an affinity to fibrin derived from a tissue plasminogen activator polypeptide and a polypeptide...
5200340 Thrombin-activated tissue plasminogen activators  
Zymogens of proteins having fibrinolytic activity are disclosed. The proteins are cleavable by thrombin, the cleavage resulting in the stimulation of fibrinolytic activity. Suitable proteins which...
5196322 Vectors and compounds for expression of zymogen forms of human protein C  
A method for the recombinant production of zymogen forms of human protein C is described. These zymogen forms differ from native zymogen protein C in their increased sensitivity to activation by...
5190756 Methods and materials for expression of human plasminogen variant  
A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the...
5188829 Rapidly acting prourokinase  
A human prourokinase-like polypeptide having the following amino acid sequence: (Met).Ser 1 -X 156 .Y 157 .Z 158 -- wherein Met is an occasionally present methionine, Ser is the first...
5187098 DNA encoding hybrid streptokinases with plasminogen fibrin binding domains  
Compositions and methods of the synthesis of hybrid streptokinase with fibrin binding domains based on gene fusion technology. Recombinant DNA methods have been used to fuse gene segments for...
5185259 Truncated human tissue plasminogen activator  
Human tissue plasminogen activator (t-PA) is produced in useful quantities using recombinant DNA techniques. The invention disclosed thus enables the production of t-PA free of contaminants with...
5183754 Method for production of human tissue type plasminogen activator  
A method for the production of human tissue type plasminogen activator (human t-PA) using cells is disclosed. The method comprises producing the human t-PA in parallel with the growth of the cells...
5168061 Human chorionic peptidase-1  
A chorionic peptidase-1 (C-ase-1) which is isol The U.S. government may have rights concerning the present invention because relevant developmental work was supported by NIH grant No. HD 14842.
5158882 Method for purifying a crude tissue plasminogen activator preparation  
Separation of tPA and undesired proteins is securely and effectivity accomplished by using a cation-exchanger in the two step procedure for selective elution of undesired proteins from the...
5156969 Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties  
A tissue plasminogen activator (t-PA) variant is prepared that has an amino acid deletion at positions 466 to 470 of the corresponding wild-type t-PA. This alteration renders the variant fibrin...
5151358 Processes for the recovery of naturally produced chymosin  
Disclosed are methods for the recovery and purification of naturally produced chymosin. In particular, disclosed are methods for the recovery and purification of chymosin from aqueous solutions...
5151268 Methods of using recombinant human protein C  
The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that...
5151359 Method for producing of human tissue type plasminogen activator  
A method for the production of human tissue type plasminogen activator (tPa) using cells is disclosed. The method includes a supplementation of a p-aminomethyl benzoic acid derivative to a cell...
5149533 Modified t-PA with kringle-/replaced by another kringle  
Tissue plasminogen activator analogs exhibiting greater specificity for fibrin than native t-PA are disclosed. The analogs include the K1 domain of native t-PA replaced with another kringle domain...
5141862 Method of purifying tpa or plasminogen activator using a tripeptide of the formula: -X-Y-argininal wherein X and Y are selected from the group consisting of pro,phe,trp and tyr  
A method for purifying tPA or a plasminogen activator having an active site resembling that of tPA from an impure solution thereof which comprises contacting the impure solution with a solid...
5141863 Purification procedure of TPA from crude preparations  
Tissue plasminogen activator (tPA) species having a specific molecular weight can be isolated in a purified form from a crude tPA preparation containing various tPA species having different...
5139936 Use of the GAL1 yeast promoter  
A DNA segment contains a GAL1 promoter of Saccharomyces cerevisae linked to a gene other than the galoctokinase gene, for directing the expression of the gene within a yeast cell. A GAL1 promoter...
5139944 Collagen-specific enzyme with platelet aggregation inhibition properties  
The collagenase is like tissue collagenases in that it cleaves collagen at a single site. The collagenase which has a molecular weight of about 50 k daltons, specifically inhibits collagen-induced...
5139943 Processes for the recovery of microbially produced chymosin  
Disclosed are methods for the recovery of microbially produced chymosin. In particular, disclosed are methods for the recovery of chymosin from the fermentation beer arising from culturing...
5134065 Tissue plasminogen activator inhibitor and method of purification  
A novel and unique plasminogen activator inhibitor fragment is obtained from human umbilical vein endothelial cells which has the following characteristics: A. it is derived from a native t-PA...
5132407 Purified inducible nitric oxide synthase flavoprotein  
Inducible nitric oxide (NO) synthase flavoprotein purified to an activity more than 400-fold from activated mouse macrophage cell line is water soluble, has a denatured molecular mass as determined...
5130143 Use of a low affinity-heparin fraction in conjunction with t-PA for thrombolytic therapy  
A composition for thrombolytic therapy includes a tissue-type plasminogen activator (t-PA) and a low affinity heparin fraction. The composition is administered intravenously to allow the t-PA to...
5120537 Factor Xa based anticoagulant compositions  
An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a...
5116731 Process for the detection of an allergy or an anti-allergic substance  
The present invention provides a one-step process for the detection of the presence of an allergy and for the specific detection of the allergen responsible for the allergy, in which the leukocytes...
5110736 Purificaiton procedure of tPA from crude preparations  
Crude tPA containing, as an impurity, a protein which is reactive with an anti-human tPA antibody and has a molecular weight of 110,000±20,000 daltons is purified by bringing the crude tPA into...
Matches 401 - 450 out of 569 < 1 2 3 4 5 6 7 8 9 10 11 12 >